XCancer

CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma

Description:

This is a prospective study to evaluate the sensitivity and specificity of Cu-64 DOTA-ECL1i PET/CT imaging to serve as a novel precision imaging tool for patients with head and neck squamous cell carcinoma (HNSCC).

Sponsor:

Washington University School of Medicine

Phase:

Phase 2

Contacts:

Farrokh Dehdashti, MD (PRINCIPAL_INVESTIGATOR)

Farrokh Dehdashti, MD (CONTACT)

dehdashtif@wustl.edu

314-362-1474

Government Study Link:

NCT07659678 - Click here to see study on

ClinicalTrials.gov

ECL1i

Isotope(s):
Target(s):
  • CCR2
Ligand Class: Peptides
Chelator: DOTA
Inclusion
  • Lesion size of at least 1.0 cm in longest dimension by conventional imaging.
  • Cohort 1: Newly diagnosed locally advanced T3-T4a, N0-3 and M0 squamous cell head and neck cancer scheduled to undergo standard of care surgery with or without neoadjuvant therapy OR Cohort 2: Suspected or biopsy proven recurrent/metastatic squamous cell head and neck cancer scheduled to undergo first-line anti-PD1 therapy. HPV status does not need to be known and both HPV+ and HPV- subjects are eligible to enroll
Exclusion

Exclusion Criteria Not Yet Provided